# A Study of Olomorasib (LY3537982) in Participants With Advanced Colorectal Cancer and a KRAS G12C Mutation

Source: https://onco.cc/trials/nct07814417/  
OnCo record `nct07814417` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of olomorasib, cetuximab, fOLFOX (5-FU, leucovorin, oxaliplatin) and fluorouracil (5-FU) in colorectal cancer, run by Eli Lilly and Company, not yet recruiting.

## Summary

A Study of Olomorasib (LY3537982) in Participants With Advanced Colorectal Cancer and a KRAS G12C Mutation is a phase 2, interventional study registered as NCT07814417 by Eli Lilly and Company, with a registry enrolment figure of 50 participants, started 2026-10 and due to reach its primary completion in 2028-11. Interventions recorded: Olomorasib; Cetuximab; Oxaliplatin; Leucovorin/levofolinate calcium; 5-fluorouracil. Conditions listed: Colorectal Neoplasms. Primary outcome: Overall Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1; Progression-Free Survival (PFS) Per RECIST v1.1. Colorectal eligibility wording from the registry: "* Histologically or cytologically confirmed colorectal cancer (CRC) with Stage III or Stage IV disease, not suitable for curative intent radical surgery or radiation therapy". No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT07814417
- Phase: 2
- Setting: A Phase 2, Open-Label Study to Evaluate the Safety and Efficacy of Olomorasib in Combination With Cetuximab and mFOLFOX6 in Participants With KRAS G12C-Mutant, Locally Advanced Unresectable or Metastatic Colorectal Cancer
- Sponsor: Eli Lilly and Company
- Enrolled: 50

## Sources

- ClinicalTrials.gov NCT07814417: https://clinicaltrials.gov/study/NCT07814417

## Connected records

- cancers: [Colon cancer (adenocarcinoma of the colon)](https://onco.cc/cancers/colon-cancer/), [KRAS G12C-mutant colorectal cancer](https://onco.cc/cancers/kras-g12c-colorectal/), [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [KRAS & RAS inhibitors](https://onco.cc/technologies/kras-inhibitors/), [Monoclonal antibodies](https://onco.cc/technologies/monoclonal-antibody/), [Platinum agents](https://onco.cc/technologies/platinum/)
- drugs: [Cetuximab](https://onco.cc/drugs/cetuximab/), [Fluorouracil (5-FU)](https://onco.cc/drugs/fluorouracil/), [FOLFOX (5-FU, leucovorin, oxaliplatin)](https://onco.cc/drugs/folfox/), [Olomorasib](https://onco.cc/drugs/olomorasib/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07814417.json